“…For example, on one hand, as transcriptional coactivators of estrogen receptor alpha, they may contribute to the proliferative effect of estradiol on breast cancer cells (Wortham et al, 2009;Dutertre et al, 2010a) and, as coregulators of betacatenin, they may contribute to the epithelial to mesenchymal transition, which has been associated with breast cancer progression (Yang et al, 2006). On the other hand, as coactivators of p53 and Smad, ddx5/ ddx17 may exert tumor suppressor functions (Warner et al, 2004;Bates et al, 2005). However, oncogenic functions or tumor suppressor roles of ddx5 and ddx17 are still a matter of debate and could be contextdependent (Fuller-Pace and Moore, 2011).…”